Metis TechBio Co (HKSE:07666) EBIT: HK$-159.15 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:07666 Metis TechBio Co Ltd HKSE:07666
6 GF Score
Price HK$12.24
! 1 Warning Sign
View Full Analysis

What is Metis TechBio Co EBIT?

Metis TechBio Co HKSE:07666 +2.00% 6 EBIT is HK$-159.15 Mil as of Dec. 2025. GuruFocus rates HKSE:07666 with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

Metis TechBio Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was HK$-159.15 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-159.15 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Metis TechBio Co's annualized ROC % for the quarter that ended in Dec. 2025 was -219.00%. Metis TechBio Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -677.40%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Metis TechBio Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -1.22%.

Metis TechBio Co  (HKSE:07666) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Metis TechBio Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-628.952 * ( 1 - 0% )/( (279.45 + 294.933)/ 2 )
=-628.952/287.1915
=-219.00 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1475.906 - 46.383 - ( 1227.257 - max(0, 187.466 - 1337.539+1227.257))
=279.45

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1425.391 - 51.434 - ( 1243.373 - max(0, 190.243 - 1269.267+1243.373))
=294.933

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Metis TechBio Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-636.584/( ( (81.76 + max(-13.875, 0)) + (106.188 + max(-99.675, 0)) )/ 2 )
=-636.584/( ( 81.76 + 106.188 )/ 2 )
=-636.584/93.974
=-677.40 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(93.501 + 0 + 15.961) - (46.383 + 0 + 76.954)
=-13.875

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.2 + 0 + 25.212) - (51.434 + 0 + 73.653)
=-99.675

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Metis TechBio Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-159.146/13031.887
=-1.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metis TechBio Co EBIT Related Terms

Metis TechBio Co EBIT Historical Data

* Premium members only.

The historical data trend for Metis TechBio Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metis TechBio Co EBIT Chart

Metis TechBio Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBIT
-570.22 -561.59 -353.07 -397.60

Metis TechBio Co Quarterly Data
Dec22 Dec23 Dec24 Sep25 Dec25
EBIT 0.00 0.00 -84.55 0.00 -159.15

HKSE:07666 vs VRTX, REGN, RVMD: EBIT Comparison

For the Biotechnology subindustry, Metis TechBio Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Metis TechBio Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Metis TechBio Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Metis TechBio Co's EV-to-EBIT falls into.


HKSE:07666
6GF Score
Metis TechBio Co Ltd HKSE:07666
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metis TechBio Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-159.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of HK$-159.15 Mil mean?
Metis TechBio Co (HKSE:07666) has a EBIT of HK$-159.15 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Metis TechBio Co.
Is Metis TechBio Co's EBIT too high?
Metis TechBio Co's current EBIT is HK$-159.15 Mil. Overall, Metis TechBio Co has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Metis TechBio Co's EBIT compare to VRTX and REGN?
Metis TechBio Co's EBIT of HK$-159.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Metis TechBio Co. Metis TechBio Co's current EBIT is HK$-159.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metis TechBio Co stock overvalued right now?
Metis TechBio Co (HKSE:07666) has a current EBIT of HK$-159.15 Mil. The current EBIT is HK$-159.15 Mil. Metis TechBio Co's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Metis TechBio Co (HKSE:07666), the current EBIT is HK$-159.15 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Metis TechBio Co Business Description

Other Exchanges RO9:Germany
Address No. 21 Tianhe West Road, Room 201, 2nd Floor, Building 13, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing, CHN
Metis TechBio Co Ltd is an investment holding company. The company and its subsidiaries are principally engaged in AI-empowered nanomaterial innovation for the delivery and application of active agents across all carbon-based life forms. Its technology platform, NanoForge, comprises a set of integrated tools, including a lipid library, AI models, an AI agent (METiS), quantum chemistry and molecular dynamics simulations, and high-throughput screening platforms. The company has developed three solution platforms (AiTEM, AiLNP, and AiRNA) designed to simulate, predict, and interpret nanoscale interactions, enabling the rational design, optimization, and validation of nanomaterials and their associated payloads.
6GF Score

Get the complete analysis for HKSE:07666

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$12.24
Price